Novacyt S.A. (LSE:NCYT) has released an unaudited trading update for the first half of 2025, indicating group revenue of approximately £9.8 million. While this represents a modest year-on-year decline, the company highlighted notable progress in its clinical division and growing adoption of its non-invasive prenatal testing (NIPT) technologies, especially within the Asia-Pacific region.
The company emphasized its strong financial footing, remaining entirely debt-free and maintaining a robust cash reserve. This financial strength is expected to support its trajectory toward achieving EBITDA profitability in the near term.
A key highlight of the period was the launch of LightBench® Discover, a new genomics platform designed to accelerate research capabilities. This innovation marks a significant step forward for Novacyt following its recent corporate restructuring and strengthens its position in the genomic research field.
About Novacyt
Novacyt is a global molecular diagnostics provider specializing in genomic medicine. The company offers a comprehensive range of integrated technologies and services, supporting diagnostic applications across human and animal health as well as environmental monitoring.
Its operations span three core segments: Clinical, Instrumentation, and Research Use Only. With a commercial footprint in more than 65 countries, Novacyt continues to serve a diverse and growing international market.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply